Literature DB >> 9642266

Mutations at nonliganding residues Tyr-85 and Glu-83 in the N-lobe of human serum transferrin. Functional second shell effects.

Q Y He1, A B Mason, R C Woodworth, B M Tam, R T MacGillivray, J K Grady, N D Chasteen.   

Abstract

The x-ray crystal structure of the N-lobe of human serum transferrin has shown that there is a hydrogen bond network, the so-called "second shell," around the transferrin iron binding site. Tyrosine at position 85 and glutamic acid at position 83 are two nonliganding residues in this network in the human serum transferrin N-lobe (hTF/2N). Mutation of each of these two amino acids has a profound effect on the metal binding properties of hTF/2N. When Tyr-85 is mutated to phenylalanine, iron release from the resulting mutant Y85F is much more facile than from the parent protein. Elimination of the hydrogen bond between Tyr-85 and Lys-296 appears to interfere with the "di-lysine (Lys-206-Lys-296) trigger," which affects the iron binding stability of the protein. Surprisingly, mutation of Glu-83 to alanine leads to the absence of one of the normal iron binding ligands; introduction of a monovalent anion is able to restore the normal first coordination sphere. The missing ligand appears to be His-249, as revealed by comparison of the metal binding behaviors of mutants H249Q and E83A and structural analysis. Glu-83 has a strong H bond linkage with His-249 in apo-hTF/2N, which helps to hold the His-249 in the proper position for iron binding. Disabling Glu-83 by mutation to an alanine seriously disturbs the H bond network, allowing His-249 to move away. A monovalent anion can help reestablish the normal network by providing a negative charge near the position of Glu-83 to reach charge balance, so that ligand His-249 is available again for iron binding.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9642266     DOI: 10.1074/jbc.273.27.17018

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  7 in total

1.  Crystal structures of two mutants (K206Q, H207E) of the N-lobe of human transferrin with increased affinity for iron.

Authors:  A H Yang; R T MacGillivray; J Chen; Y Luo; Y Wang; G D Brayer; A B Mason; R C Woodworth; M E Murphy
Journal:  Protein Sci       Date:  2000-01       Impact factor: 6.725

2.  Role of conserved glycine in zinc-dependent medium chain dehydrogenase/reductase superfamily.

Authors:  Manish Kumar Tiwari; Raushan Kumar Singh; Ranjitha Singh; Marimuthu Jeya; Huimin Zhao; Jung-Kul Lee
Journal:  J Biol Chem       Date:  2012-04-12       Impact factor: 5.157

3.  [13C]Methionine NMR and metal-binding studies of recombinant human transferrin N-lobe and five methionine mutants: conformational changes and increased sensitivity to chloride.

Authors:  Q Y He; A B Mason; B M Tam; R T MacGillivray; R C Woodworth
Journal:  Biochem J       Date:  1999-12-15       Impact factor: 3.857

4.  The chloride effect is related to anion binding in determining the rate of iron release from the human transferrin N-lobe.

Authors:  Q Y He; A B Mason; V Nguyen; R T MacGillivray; R C Woodworth
Journal:  Biochem J       Date:  2000-09-15       Impact factor: 3.857

5.  Large cooperativity in the removal of iron from transferrin at physiological temperature and chloride ion concentration.

Authors:  David H Hamilton; Isabelle Turcot; Alain Stintzi; Kenneth N Raymond
Journal:  J Biol Inorg Chem       Date:  2004-10-29       Impact factor: 3.358

6.  Structural and functional consequences of the substitution of glycine 65 with arginine in the N-lobe of human transferrin.

Authors:  Anne B Mason; Peter J Halbrooks; Nicholas G James; Shaina L Byrne; John K Grady; N Dennis Chasteen; Cedric E Bobst; Igor A Kaltashov; Valerie C Smith; Ross T A MacGillivray; Stephen J Everse
Journal:  Biochemistry       Date:  2009-03-10       Impact factor: 3.162

7.  A computational study of the open and closed forms of the N-lobe human serum transferrin apoprotein.

Authors:  David Rinaldo; Martin J Field
Journal:  Biophys J       Date:  2003-12       Impact factor: 4.033

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.